Acasă › Carcinom cu celule scuamoase de cap și gât › Pennsylvania › Pittsburgh
Studii clinice pentru Carcinom cu celule scuamoase de cap și gât în Pittsburgh, PA
22 studii pentru Carcinom cu celule scuamoase de cap și gât caută participanți în și în jurul orașului Pittsburgh (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
În curs de recrutareFaza 3
- Allegheny General Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- și încă 7
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
În curs de recrutareFaza 2/3
- Site #0103, Pittsburgh
- Site #0123, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
În curs de recrutareFaza 1
- Exelixis Clinical Site #32, Pittsburgh
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
În curs de recrutareFaza 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- și încă 4
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
În curs de recrutareFaza 1
- Research Site, Pittsburgh
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
În curs de recrutareFaza 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
În curs de recrutareFaza 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
În curs de recrutareFaza 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- și încă 9
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
În curs de recrutareFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- Research Site, Pittsburgh
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
În curs de recrutareFaza 2/3
- UPMC-Magee Womens Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
În curs de recrutareFaza 2
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- și încă 5
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
În curs de recrutareFaza 2
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
În curs de recrutareFaza 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
În curs de recrutareFaza 3
- GSK Investigational Site, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
În curs de recrutareFaza 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
În curs de recrutareFaza 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
În curs de recrutareFaza 1
- UPMC- Hillman Cancer Center, Pittsburgh
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
În curs de recrutareFaza 2
- UPMC, Pittsburgh
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
În curs de recrutareFaza 1
- UPMC Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
În curs de recrutareFaza 1/2
- University of Pittsburgh, Pittsburgh
Studii pentru Carcinom cu celule scuamoase de cap și gât în alte orașe
- Houston, TX47 studii
- Los Angeles, CA42 studii
- Boston, MA40 studii
- New York City, NY39 studii
- Nashville, TN39 studii
- St. Louis, MO28 studii
- Arlington, VA26 studii
- Philadelphia, PA26 studii
- Chicago, IL26 studii
- Atlanta, GA24 studii
- San Antonio, TX22 studii
- New Haven, CT22 studii
Alte studii în Pittsburgh
- Cancer pulmonar cu celule non-pătrate48 studii
- Cancer (toate tipurile)41 studii
- Cancer de sân39 studii
- Cancer colorectal32 studii
- Cancer metastatic31 studii
- Melanom31 studii
- Cancer ovarian30 studii
- Cancer endometrial23 studii
- Cancer de prostată23 studii
- Cancer pulmonar23 studii
- Accident vascular cerebral22 studii
- Depresie22 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.